- Conditions
- Gastric Adenocarcinoma, Gastric Cancer
- Interventions
- floxuridine, 5-Fluorouracil, leucovorin, External Beam Radiotherapy, Surgery
- Drug · Procedure
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1105–1128
of 9,795
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- M7824, Pembrolizumab
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 25
- States / cities
- Huntsville, Alabama • Los Angeles, California • Orange, California + 21 more
- Conditions
- Head and Neck Cancer
- Interventions
- Oleena
- Device
- Lead sponsor
- Aptar Digital Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Carcinoma, Hepatocellular, Liver Diseases, Neoplasms by Histologic Type, Digestive System Neoplasms, Carcinoma, Liver Neoplasms, Neoplasms, Neoplasms by Site, Digestive System Diseases, Adenocarcinoma, Neoplasms, Glandular and Epithelial
- Interventions
- ABT-869, Sorafenib
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,035 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 13
- States / cities
- Beverly Hills, California • LaVerne, California • Orange, California + 8 more
- Conditions
- Advanced Solid Tumor, PDAC, HNSCC
- Interventions
- ADCE-T02
- Drug
- Lead sponsor
- Adcendo ApS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Rogers, Arkansas • New Haven, Connecticut • Boston, Massachusetts + 4 more
- Conditions
- Biliary Tract Cancer
- Interventions
- Irinotecan & Capecitabine
- Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck, Bone Cancer, Advanced Cancer, Recurrent Disease, Metastatic Tumours
- Interventions
- 177Lu-3BP-227 (also called 177Lu-IPN01087)
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myelogenous Leukemia, B-cell Lymphoma
- Interventions
- FT516, Rituximab, Obinutuzumab, Cyclophosphamide, Fludarabine, IL-2, Bendamustine
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • San Diego, California • Denver, Colorado + 4 more
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer
- Interventions
- biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
- Other · Procedure
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Neoplasms
- Interventions
- Niraparib Tablet, Niraparib Capsule
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 16
- States / cities
- Encinitas, California • Fresno, California • Denver, Colorado + 13 more
- Conditions
- Solid Tumor
- Interventions
- Oraxol
- Drug
- Lead sponsor
- Athenex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Buffalo, New York • San Antonio, Texas
- Conditions
- Solid Tumors
- Interventions
- RO7296682, Atezolizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
- Interventions
- Paclitaxel, CB-839
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Mobile, Alabama • New Haven, Connecticut + 20 more
- Conditions
- Advanced Solid Tumors
- Interventions
- RO7623066, Olaparib, Carboplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 15
- States / cities
- Orange, California • New Haven, Connecticut • Detroit, Maine + 12 more
- Conditions
- Neoplasms
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody, MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 5 more
- Conditions
- Advanced Solid Tumors, Solid Tumors, Pancreatic Cancer
- Interventions
- Defactinib, Pembrolizumab, Gemcitabine
- Biological · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • St Louis, Missouri
- Conditions
- Advanced Solid Tumors
- Interventions
- BAY2965501, Pembrolizumab, Platinum-based Chemotherapy
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
- Interventions
- Infigratinib, Tamoxifen, Omnipaque 350, Iopamidol, Computed tomography (CT)
- Drug · Diagnostic Test
- Lead sponsor
- Jennifer Lee Caswell-Jin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), Sarcoma
- Interventions
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Drug
- Lead sponsor
- Radiopharm Theranostics, Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska + 1 more
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma, Gastric Cancer
- Interventions
- FDG-PET, surgery, 5-FU, capecitabine, docetaxel, Irinotecan, 3D-CRT, IMRT
- Procedure · Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 71
- States / cities
- Los Angeles, California • St. Helena, California • Newark, Delaware + 47 more
- Conditions
- Pancreatic Cancer
- Interventions
- Celecoxib, Gemcitabine Hydrochloride
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 11
- States / cities
- Fort Smith, Arkansas • Orlando, Florida • Atlanta, Georgia + 8 more
- Conditions
- Pancreatic Cancer
- Interventions
- MEDI4736, Tremelimumab, Stereotactic Body Radiation Therapy (SBRT)
- Drug · Radiation
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • New York, New York • The Bronx, New York
- Conditions
- Fallopian Tube Cancer, Ovarian Sarcoma, Ovarian Stromal Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Uterine Sarcoma, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IV Endometrial Carcinoma, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Uterine Sarcoma, Stage IV Vulvar Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer
- Interventions
- stereotactic radiosurgery, quality-of-life assessment
- Radiation · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Metastatic Breast Cancer
- Interventions
- Dovitinib, Fulvestrant, Dovitinib Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 18
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • Duarte, California + 15 more